---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-166938"
form_type: "8-K"
ticker: "ANTX"
cik: "0001880438"
company_name: "AN2 Therapeutics, Inc."
filed_at: "2024-06-24T23:59:59+00:00"
generated_at: "2026-06-01T02:36:33.004102+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# AN2 Therapeutics shareholders elect directors, ratify PwC, approve officer exculpation amendment at 2024 annual meeting

## Summary
- 78.31% quorum with 23,360,239 shares represented; all three Class II director nominees elected.
- Margaret FitzPatrick, Patricia Martin, Melvin Spigelman each received over 17.7M votes for.
- PricewaterhouseCoopers LLP ratified as auditor: 23,344,330 for, 12,786 against.
- Amendment to certificate of incorporation for officer exculpation approved: 18,416,318 for.

## SEC filing metadata
- accession: 0001193125-24-166938
- form_type: 8-K
- ticker: ANTX
- cik: 0001880438
- company_name: AN2 Therapeutics, Inc.
- filed_at: 2024-06-24T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1880438/000119312524166938/0001193125-24-166938-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1880438/000119312524166938/d860451d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-166938
- JSON: https://secwatch.observer/filing/0001193125-24-166938.json
- Plain text: https://secwatch.observer/filing/0001193125-24-166938.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.